


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Molnupiravir. [Updated 2023 Feb 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Molnupiravir

Revised: February 15, 2023.

CASRN: 2492423-29-5



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of molnupiravir during breastfeeding. Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Nirmatrelvir, Remdesevir

Substance Identification

Substance Name

Molnupiravir

CAS Registry Number

2492423-29-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Antiviral Agents

Nucleosides